Use of the newly ineffective treatments produced by Regeneron Pharmaceuticals and Eli Lilly is highest in a dozen states. They include several Southern states with some of the nation’s lowest vaccination rates, but also California, which ranks in the nation’s top 20 for fully vaccinated residents.
The companies announced the partnership in March to develop trastuzumab deruxtecan, for which they plan to file approval later this year based on the successful Phase II study.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The long-beleaguered monoclonal antibody developer KaloBios is finally winding down operations - after a constant stream of setbacks since its February 2013 IPO.
It has three platforms: A soluble T-cell antigen receptor that zeroes in on cancerous or viral targets; a monoclonal antibody approach using tissue factor antagonists; and an IL-15 platform that's meant to harness IL-15 super-agonists, antagonists and protein scaffolds to build novel immune molecules.
Infectious diseases like dengue fever influenza of the seasonal and pandemic varieties are the top targets for Cambridge biotech Visterra, which has just raised a hefty Series B round – to the tune of $30 million – for its immunotherapies. The company plans to bring its influenza therapy into Phase 2 trial with the new cash […]
Most human monoclonal antibody therapies target proteins on the outer membrane of the cell – but a Bay Area startup is receiving a healthy flush of cash to further investigate its drug that reaches cancer cells on the inside. Cancer immunotherapy player Eureka Therapeutics has raised $21 million in a Series C financing round, led by […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.